Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open‐label studyLijuan Deng, Jun Zhu, Jianda Hu et al.|American Journal of Hematology|2023Cited by 18
Outcome and Prognostic Factors of High-Risk Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell TransplantationChengying Zhu, Chunji Gao, Guofeng Chen et al.|Annals of Transplantation|2019Cited by 14